Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2007-12-04
2007-12-04
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S179100, C424S181100, C424S182100
Reexamination Certificate
active
09671995
ABSTRACT:
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
REFERENCES:
patent: 5208020 (1993-05-01), Chari et al.
patent: 5395924 (1995-03-01), Blatter et al.
patent: 5416064 (1995-05-01), Chari et al.
patent: 5639641 (1997-06-01), Pedersen et al.
patent: 5679648 (1997-10-01), McCaffrey et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 58-167592 (1983-10-01), None
patent: 62-195387 (1987-08-01), None
patent: 2002-541088 (2002-12-01), None
patent: 2002-543093 (2002-12-01), None
patent: 2003-503365 (2003-01-01), None
patent: WO 98/08506 (1998-03-01), None
patent: WO03/070234 (2003-08-01), None
Hortobagyi, G, 1997, Docetaxel in breast cancer and a rationale for combination therapy, Oncology, vol. 11, No. 6, Suppl., pp. 11-15.
Roy, DC, et al, 1996, Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin, Journal of the National Cancer Institute, vol. 88, No. 16, pp. 1136-1145.
Krek, CE, et al, 1995, Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells, Protein Engineering, vol. 8, No. 5, pp. 481-489.
Roguska, MA, et al, 1994, Humanization of murine monoclonal antibodies through variable domain resurfacing, Proceedings of the National Academy of Sciences USA, vol. 91, No. 3, pp. 969-973.
Liu, C, et al, 1996, Cure of large human colon cancer xenografts by a C242-maystansinoid conjugate, Proceedings of the American Association for Cancer Research, vol. 37, pp. 466-467, Abstract No. 3183.
Aoe, K, et al, 1996, Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer cell line, Proceedings of the American Association for Cancer Research, vol. 37, pp. 375, Abstract No. 2560.
Lynch, TJ, et al, 1997, Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin, Journal of Clinical Oncology, vol. 15, No. 2, pp. 723-734.
Liu, C, et al, 1997, The development of antibody delivery systems to target cancer with highly potent maystansinoids, Exp. opin. Invest. Drugs, vol. 6, No. 2, pp. 169-172.
Nguyen, DM, et al, 2001, Synergistic tumoricidal effect of the paclitaxel and 17 allylamino geldanamycin (17AAG) combination in non-small cell lung cancer: in vitro and in vivo analysis, Proceedings of the Am. Assoc. for Cancer Research, vol. 42, pp. 68-69.
Trail, PA, 1999, Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin, Clinical Cancer Research, vol. 5, No. 11, pp. 3632-3638.
Morikawa, t, et al, 1995, Pulmonary malignant fibrous histiocytoma treated with cisplatin plus etoposide followed by surgery, Nihon Kyobu Shikkan Gakkai Zasshi, Japanese Journal of Thoracic Diseases, vol. 33, No. 9, pp. 993-998 (English abstract only).
Chari, RVJ, et al, 2000, Dose-response of the anti-tumor effect of huN901-DM1 against human small-cell lung cancer xenografts, Proceedings of the American Association for Cancer Research, vol. 41, pp. 693.
Yeh, YA, et al, 1995, Growth inhibitory action of brefeldin A with taxol and tiazofurin in human breast carcinoma cells, Cancer Biochemistry Biophysics vol. 15, No. 1, pp. 11-17.
Milas, L, et al, 1994, Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel, Cancer Research, vol. 54, No. 13, pp. 3506-3510.
Vogel, CL, et al, 1999, Monotherapy of metastatic breast cancer: a review of newer agents, Oncologist, vol. 4, No. 1, pp. 17-33.
Perez, EA, 1999, Paclitaxel plus nonathracycline combinations in metastatic breast cancer, Seminars in Oncology, vol. 26, No. 1, Suppl. 2, pp. 21-26.
Fornier, M, et al, 1999, Update on the management of advanced breast cancer, Oncology, vol. 13, No. 5, pp. 647-658.
Kaufman, O, et al, 1997, Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections, Human Pathology, vol. 28, No. 12, pp. 1373-1378.
Gu, WZ, et al, Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines, Anti-Cancer Research, vol. 10, No. 10, pp. 895-901.
Chan, D, et al, 1997, Synergistic effects of doxorubicin and modulators of multidrug resistance in small cell lung cancer (SCLC) cells naturally expressing MDR-1, MRP and LRP phenotypes, Proceedings Am. Assoc. for Cancer Res., vol. 38, pp. 591-592.
Gianni, L, et al, 1998, Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies, Recent Results in Cancer Research, vol. 152, pp. 314-322.
Burris, HA, III, 2000, Docetaxel (Taxotere) in HER-2-positive patients and in combination with Trastuzumab (Herceptin), Seminars in Oncology, vol. 27, No. 2, Suppl. 3, pp. 19-23.
Perez, EA, 1999, Current management of metastatic breast cancer, Seminars in Oncology, vol. 26, No. 4, Suppl. 12, pp. 1-10.
Hortobagyi, GN, 1999, Recent progress in clinical development of doxetaxel (Taxotere), Seminars in Oncology, vol. 26, No. 3, Suppl. 9, pp. 32-36.
Norton, L, et al, 1999, Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+), Proc Annu Meet Am Soc Clin Oncol, vol. 18, A483.
Schlom (Monoclonal Antibodies: They're More and Less Than You Think, In: Molecular Foundations of Oncology, 1991, Ed. S. Broder, pp. 95-134).
Chari et al (Cancer Research, 1992, vol. 52, pp. 127-131).
Siegall et al (Proc Annu Meet Am Assoc Cancer Res, 1997, vol. 38, p. A185).
The abstract of Iwasaki et al (Yakugaku Zasshi, 1998, vol. 118, pp. 111-126).
Pegram et al (Oncogene, 1999, vol. 18, pp. 2241-2251).
Watson et al (Proc Ammu Meet Am Assoc Cancer Res, 1996, vol. 37, p. A2997).
The abstract of Guchelaar et al (Clinical Oncology, 1994, vol. 6, pp. 40-48).
Liu et al (Proc Annu Meet Am Assoc Cancer Res, 1997, vol. 38, p. A190).
The abstract of Lynch et al (Journal of Clinical oncology, 1997, vol. 15, pp. 723-734).
Lidor et al (Journal of Clinical Investigation, 1993, vol. 92, pp. 2440-2447).
Rosenblum et al (Cancer Immunol Immunother, 1996, vol. 42, pp. 115-121).
Abstract of Fiorentino et al (Dev Oncol, 1988, vol. 54, pp. 415-435).
Fitzpatrick and Wheeler, International Immunopharmacology, 2003, vol. 3, pp. 1699-1714.
Fedier et al. Annals of Oncology, 2003, vol. 14, pp. 938-945.
Pegram et al (Oncogene, 1998, vol. 18, pp. 2241-2251).
ImmunoGen, Inc. Press Release (Feb. 25, 1999).
Apelgren et al, Cancer Research, 50:3540-3544 (1990).
Bai et al, Cancer Research, 56:4398-4406 (1996).
Dieras et al, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. 100, Abstract Nos. 382 and 383 (Jun. 1998).
Glisson et al, Journal of Clinical Oncology, 17(8) :2309-2315 (Aug. 1999).
Griffin et al, The Journal of Immunology, 130(6) :2947-2951 (1983).
Kibbelaar et al, Journal of Pathology, 159:23-28 (1989).
Laguzza et al, J. Med. Chem., 32:548-555 (1989).
Liu et al, Proceedings of the American Association for Cancer Research, 38:29 Abstract No. 190 (1997).
Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (1996).
Morris et al, Journal of Clinical Oncology, 16(3) :1094-1098 (Mar. 1998).
Panda et al, Proc. Natl. Acad. Sci. USA, 95:9313-9318 (Aug. 1998).
Pitot et al, Clinical Cancer Research, 5:525-531 (Mar. 1999).
Pettit et al, J. Am. Chem. Soc., 111:5463-5465 (1989).
Roguska et al, Protein Engineering, 9(10) :895-904 (1996).
Roguska et al, Proc. Natl. Acad. Sci. USA, 91:969-973 (1994).
Rygaard et al, Br. J. Cancer, 65:573-577 (1992).
S
Canella Karen A.
Immunogen Inc.
Sughrue Mion Pllc.
LandOfFree
Compositions and methods for treating cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896414